Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
P04451
Phase 2 small_molecule completed
Quick answer
Buprenorphine hydrochloride marketed sublingual tablet (Subutex) for Opioid Dependency is a Phase 2 program (small_molecule) at Indivior Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Indivior Pharmaceuticals
- Indication
- Opioid Dependency
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed